NCT02857270 2022-11-22A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic CancerEli Lilly and CompanyPhase 1 Completed210 enrolled
NCT02745769 2019-03-05A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted AgentsEli Lilly and CompanyPhase 1 Completed23 enrolled